Theme 1 Genetics and genomics

Acknowledgments

The authors thank the patients and unaffected individuals for participation in the Project MinE ALS Sequencing Consortium. This study was supported by different funding agencies including, but not limited to: the ALS Foundation Netherlands, the Belgian ALS Liga and National Lottery, and Agency for Innovation by Science and Technology (IWT), and the MND Association (UK). More at www.projectmine.com

Acknowledgments

Project MinE; MND Association.

Acknowledgments

We acknowledge the generous contributions of many Australians in raising money for ALS research as part of the 2014 Ice Bucket Challenge, awarded to SALSA-SGC through the Motor Neurone Disease Research Institute of Australia (MNDRIA). Our work is also supported by the Australian National Health and Medical Research Council and by the participating ALS clinics across Australia.

Acknowledgments

Funding for this study was provided by MND Association, samples from the MND Collections and Kings's College London brain bank and whole genome sequencing data from Project MinE.

Acknowledgments

Funding for this study was provided by the Government of Catalonia from grants 2014SGR1115 and RD10-1-0072 and by the Spanish Ministry of Health from grants FIS-FEDER PI16/01673, FIS-FEDER PI18/00691 and SAF2017-88076-R. The authors declare no conflicts of interest.

Acknowledgments

We would like to thank patients and donors for being part of this study. Funding for this study was provided by the Pathological Society, and the British Neuropathological Society. The authors declare no conflicts of interest.

Acknowledgments

This work was supported by grants from the Italian Agency for Research on ALS–ARiSLA (Pilot project “LNCinALS”2015-2016 and Full project “GRANULOPATHY”2015-2017). This work was also supported by “Fondazione Regionale per la Ricerca Biomedica” (FRRB 2015-0023).

Acknowledgments

GM604 is an investigational drug product developed by Genervon Biopharmaceuticals, LLC (Pasadena, CA). DK is an executive of Genervon with ownership interest. KB and WRS has received consulting fees from Genervon Biopharmaceuticals.

Acknowledgments

We would like to thank patients and their caregivers for taking part in this study. Funding for this study was provided by the National Institutes of Health from grants AG043503, AG017856, NS106754-01 and from the Dana Foundation. The authors declare no conflicts of interest.

Acknowledgments

Special thanks to Elaine Cleary.

Acknowledgments

University of Malta Research Fund and ALS Malta Foundation

Acknowledgments

This work was partially supported by OnWebDuals project (JPND-PS/0001/2013) and MG holds a grant from the project. This is an EU Joint Programme - Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organization under the aegis of JPND - www.jpnd.eu: Germany, Bundesministerium für Bildung und Forschung (BMBF); Poland, Narodowe Centrum Badań i Rozwoju (NCBiR); Portugal, Fundação a Ciência e a Tecnologia (FCT); Sweden, Vetenskapsrådet (VR).

Acknowledgments

We are indebted to our patients for providing samples for this study. Special thanks to all neurologist in the countryside of Mongolia who have assisted in reaching the most distantly located ALS patients in Mongolia. This work was funded by the Science and Technology fund from Ministry of Education and Science of Mongolia - Funding number SST-036/2015, and by German Academic Exchange Service (DAAD) - Research grants for Doctoral programmes in Germany 15\16, Funding programme number 57129429.

Acknowledgments

The authors thank all the participants. This work was supported by the Natural Science Foundation of China (Grant No. 81571247) and the National Key Research and Development Program of China (Grant No. 2016YFC0901504).

Acknowledgments

This work was supported by the National Key Research and Development Program of China (Grant number: 2016YFC0905100; 2016YFC0905103); the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS) (Grant number: 2016-12M-1-002; 2016-12M-1-004); the National Natural Science Foundation of China (NSFC) (Grant number: 81230015).

Acknowledgments

We would like to thank the patients who participated in this study. This work was supported by the Ministry of Science and Technology, Taiwan (105-2628-B-075-002-MY3), Taipei Veterans General Hospital (V107C-035) and Taiwan Motor Neuron Disease Association.

Acknowledgments

This study was supported by the grants from the Brain Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT (NRF-2017M3C7A1025364).

Acknowledgments

This study was supported by the grants from the Brain Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT (NRF-2017M3C7A1025364).

Acknowledgments

JG is the recipient of a FIS-FEDER PI16/01673. JMVT, CG, and MS are the recipients of a FIS-FEDER PI18/00691 grant.

Acknowledgments

This study received support from The Motor Neurone Disease Association of England, Wales and Northern Ireland; Science Foundation Ireland and the Kugelman Honors Program at University of West Florida.

Acknowledgments

Joost vd Westhuizen Centre for Neurodegeneration for funding; Coriell Institute for Medical Research for DNA samples with C9-allele expansions.

Acknowledgments

This work was supported by Adelis Foundation, by ALS Association grant number 47717 and by Kahn Foundation.